Correlation Between Visa and Immix Biopharma
Can any of the company-specific risk be diversified away by investing in both Visa and Immix Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Visa and Immix Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Visa Class A and Immix Biopharma, you can compare the effects of market volatilities on Visa and Immix Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Visa with a short position of Immix Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Visa and Immix Biopharma.
Diversification Opportunities for Visa and Immix Biopharma
-0.57 | Correlation Coefficient |
Excellent diversification
The 3 months correlation between Visa and Immix is -0.57. Overlapping area represents the amount of risk that can be diversified away by holding Visa Class A and Immix Biopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Immix Biopharma and Visa is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Visa Class A are associated (or correlated) with Immix Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Immix Biopharma has no effect on the direction of Visa i.e., Visa and Immix Biopharma go up and down completely randomly.
Pair Corralation between Visa and Immix Biopharma
Taking into account the 90-day investment horizon Visa Class A is expected to generate 0.18 times more return on investment than Immix Biopharma. However, Visa Class A is 5.56 times less risky than Immix Biopharma. It trades about 0.25 of its potential returns per unit of risk. Immix Biopharma is currently generating about -0.01 per unit of risk. If you would invest 31,612 in Visa Class A on December 1, 2024 and sell it today you would earn a total of 4,659 from holding Visa Class A or generate 14.74% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Against |
Strength | Very Weak |
Accuracy | 100.0% |
Values | Daily Returns |
Visa Class A vs. Immix Biopharma
Performance |
Timeline |
Visa Class A |
Immix Biopharma |
Visa and Immix Biopharma Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Visa and Immix Biopharma
The main advantage of trading using opposite Visa and Immix Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Visa position performs unexpectedly, Immix Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Immix Biopharma will offset losses from the drop in Immix Biopharma's long position.Visa vs. American Express | Visa vs. PayPal Holdings | Visa vs. Capital One Financial | Visa vs. Upstart Holdings |
Immix Biopharma vs. ZyVersa Therapeutics | Immix Biopharma vs. Hepion Pharmaceuticals | Immix Biopharma vs. Cns Pharmaceuticals | Immix Biopharma vs. Sonnet Biotherapeutics Holdings |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Other Complementary Tools
Global Correlations Find global opportunities by holding instruments from different markets | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
CEOs Directory Screen CEOs from public companies around the world | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |